Medidur delivery technology under test for treating dry-AMD

Published: 17-Dec-2008
Sustainability Drug Delivery Research & Development Pharmaceutical

Drug delivery company pSivida has started a clinical trial using its Medidur delivery technology to treat a form of dry-Age related Macular Degeneration (dry-AMD).


Drug delivery company pSivida has started a clinical trial using its Medidur delivery technology to treat a form of dry-Age related Macular Degeneration (dry-AMD).

Medidur is a tiny intravitreal insert for administration by an eye care professional, using a proprietary 25-gauge inserter in a minimally invasive, outpatient procedure.

This application of Medidur technology has been licensed to Alimera Sciences and is in Phase III clinical trials for the treatment of diabetic macular edema (DME), a potentially blinding disease that affects more than 1,000,000 people in the US. If approved by the FDA, Alimera will market the product under the name Iluvien.

The new pilot study will assess the safety and efficacy of Iluvien in patients with bilateral geographic atrophy (GA) secondary to dry-AMD and will compare two doses of Iluvien with a "sham" injection. With the 'sham' injection, everything up to actual insertion of a device takes place. The person receiving the 'sham' injection would not know that nothing was being injected because the eye is anaesthetised, just as it would be for the actual insertion.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  3. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  4. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Subscribe now